Clinical Trial: The R-E-V-I-V-A-L Study

U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT06992674) titled 'The R-E-V-I-V-A-L Study' on May 09.

Brief Summary: Vestibular migraine (VM) is one of the most common vestibular disorders, affecting 1.0% to 2.7% of the general population1, 7% of patients with definite migranous vertigo in dizziness clinics2, as well as 10.3% of VM patients in headache clinics3; 65% to 85% of VM patients are female1. Despite the relative prevalence of vestibular migraine, evidence-based medicine remains scarce. Two Cochrane reviews published in 2023 found that there is almost no evidence to support the use of medications for the acute treatment or preventive treatment of VM4,5.

Calcitonin gene-related peptide (CGR...